Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCR-alpha/beta Depleted HSCT for Hematologic Malignancies
NCT03615105Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2018
- Primary completion
- Mar 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of TCRαβ+ T cell-depleted hematopoietic stem cells in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and 6 more, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Number of Incidences of Grade 3-4 Acute Graft-versus-Host Disease at 2 years. Started Jul 2018; status: terminated.
02
Drugs
TCRαβ+ T cell-depleted hematopoietic stem cells
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)chronic myeloid leukemia (CML)Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03615105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03615105.